The invisible advantage: how rigour fuels reliability in drug development

Far from being a compliance checkbox, quality is the decisive factor that separates consistent process optimisation from costly setbacks

You need to be a subscriber to read this article.
Click here to find out more.

Quality is often described as table stakes in pharmaceutical development. It’s the baseline expectation that’s non-negotiable.

The invisible advantage: how rigour fuels reliability in drug development

Every organisation must follow good manufacturing practice (GMP) principles, maintain compliance and deliver safe, effective products.

But when something is taken as a given, it’s easy for its strategic importance to be overlooked.

Jennifer Cannon, PhD, President of Commercial Operations at Thermo Fisher Pharma Services, investigates.

In reality, quality is the most decisive competitive advantage in drug development.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like